Carl Zeiss Meditec : No change in FY guidance at this stage
>EBIT a positive surprise in Q2 - The company reported Q2 results, which came in above expectations on the bottom line. Sales were € 445.2m in Q2, 1% below our forecast, 1% above consensus (Vara). Both divisions performed according to expectations. On EBIT though, Q2 was a positive surprise with €103m in EBIT achieved vs € 88.6m our estimate and € 92.9m consensus. While the margin in Ophthalmic Devices was down as expected, it was only down 70bp y-o-y, from 22.7% to ...Carl Zeiss Meditec is a holding company. Co.'s businesses are focused on two primary areas: Ophthalmology and Microsurgery. In Ophthalmology, Co.'s operations are divided in to two strategic business units: Ophthalmic Systems, which includes a range of laser and diagnostic systems for ophthalmology; and Surgical Ophthalmology, which consists of activities in the field of ophthalmic implants and consumables. In Microsurgery, Co. provides surgical microscopes and visualization solutions, e. g. for ear, nose and throat surgery, or neurosurgery. These products are mainly used to assist with the removal of tumors, as well as the treatment of vascular diseases and functional disorders.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.